BMO Capital Downgrades Stealth BioTherapeutics (MITO) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts MITO Hot Sheet
Price: $0.32 --0%
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
5 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
BMO Capital analyst Matthew Luchini downgraded Stealth BioTherapeutics (NASDAQ: MITO) from Outperform to Market Perform with a price target of $7.00 (from $28.00).
For an analyst ratings summary and ratings history on Stealth BioTherapeutics click here. For more ratings news on Stealth BioTherapeutics click here.
Shares of Stealth BioTherapeutics closed at $13.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- H.C. Wainwright Downgrades Avalo Therapeutics Inc. (AVTX) to Neutral
- Freedom Broker Downgrades Valero Energy (VLO) to Sell
Create E-mail Alert Related Categories
DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
